Trials in kidney disease--time to EVOLVE.
暂无分享,去创建一个
[1] K. Mahaffey,et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.
[2] A. Hayen,et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.
[3] R. Temple,et al. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus , 2010, Reviews in Endocrine and Metabolic Disorders.
[4] M. Pitt,et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. , 2007, Health technology assessment.
[5] J. Craig,et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.